ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Advantages of PDE5i in the Management of Glucose Metabolism Disorders
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 187306" data-attributes="member: 13851"><p>[ATTACH=full]10796[/ATTACH]</p><p><strong>Figure 1: <span style="color: rgb(184, 49, 47)">Schematic representation of PDE5i action in insulin-related pathways. </span>PKG activated by cGMP exerts positive effects on IRS downstream effectors. The phosphorylation of PKB/AKT induces the translocation of GLUT4 vesicles on the plasma membrane, favoring glucose uptake and activation of downstream signaling involved in protein synthesis, cell growth, and differentiation. The balance between cGMP synthesis <span style="color: rgb(184, 49, 47)">(induced by the interaction of NO with sGC) </span>and cGMP hydrolysis <span style="color: rgb(184, 49, 47)">(by PDE5)</span> regulates cGMP levels. The action of the PDE5i promotes the accumulation of cGMP.<span style="color: rgb(44, 130, 201)"> IR:</span><span style="color: rgb(0, 0, 0)"> insulin receptor; </span><span style="color: rgb(44, 130, 201)">NO:</span><span style="color: rgb(0, 0, 0)"> nitric oxide; </span><span style="color: rgb(44, 130, 201)">sGC: </span><span style="color: rgb(0, 0, 0)">guanylyl cyclase; </span><span style="color: rgb(44, 130, 201)">PDE5:</span><span style="color: rgb(0, 0, 0)"> phosphodiesterase type 5; </span><span style="color: rgb(44, 130, 201)">GMP:</span><span style="color: rgb(0, 0, 0)"> guanosine monophosphate; </span><span style="color: rgb(44, 130, 201)">cGMP:</span><span style="color: rgb(0, 0, 0)"> cyclic guanosine monophosphate; </span><span style="color: rgb(44, 130, 201)">IRS: </span><span style="color: rgb(0, 0, 0)">insulin receptor substrate; </span><span style="color: rgb(44, 130, 201)">PI3K:</span><span style="color: rgb(0, 0, 0)"> phosphatidylinositol 3- kinase; </span><span style="color: rgb(44, 130, 201)">PKB/AKT:</span><span style="color: rgb(0, 0, 0)"> protein kinase B/AKT; and </span><span style="color: rgb(44, 130, 201)">mTOR: </span><span style="color: rgb(0, 0, 0)">mammalian target of rapamycin. </span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 187306, member: 13851"] [ATTACH type="full"]10796[/ATTACH] [B]Figure 1: [COLOR=rgb(184, 49, 47)]Schematic representation of PDE5i action in insulin-related pathways. [/COLOR]PKG activated by cGMP exerts positive effects on IRS downstream effectors. The phosphorylation of PKB/AKT induces the translocation of GLUT4 vesicles on the plasma membrane, favoring glucose uptake and activation of downstream signaling involved in protein synthesis, cell growth, and differentiation. The balance between cGMP synthesis [COLOR=rgb(184, 49, 47)](induced by the interaction of NO with sGC) [/COLOR]and cGMP hydrolysis [COLOR=rgb(184, 49, 47)](by PDE5)[/COLOR] regulates cGMP levels. The action of the PDE5i promotes the accumulation of cGMP.[COLOR=rgb(44, 130, 201)] IR:[/COLOR][COLOR=rgb(0, 0, 0)] insulin receptor; [/COLOR][COLOR=rgb(44, 130, 201)]NO:[/COLOR][COLOR=rgb(0, 0, 0)] nitric oxide; [/COLOR][COLOR=rgb(44, 130, 201)]sGC: [/COLOR][COLOR=rgb(0, 0, 0)]guanylyl cyclase; [/COLOR][COLOR=rgb(44, 130, 201)]PDE5:[/COLOR][COLOR=rgb(0, 0, 0)] phosphodiesterase type 5; [/COLOR][COLOR=rgb(44, 130, 201)]GMP:[/COLOR][COLOR=rgb(0, 0, 0)] guanosine monophosphate; [/COLOR][COLOR=rgb(44, 130, 201)]cGMP:[/COLOR][COLOR=rgb(0, 0, 0)] cyclic guanosine monophosphate; [/COLOR][COLOR=rgb(44, 130, 201)]IRS: [/COLOR][COLOR=rgb(0, 0, 0)]insulin receptor substrate; [/COLOR][COLOR=rgb(44, 130, 201)]PI3K:[/COLOR][COLOR=rgb(0, 0, 0)] phosphatidylinositol 3- kinase; [/COLOR][COLOR=rgb(44, 130, 201)]PKB/AKT:[/COLOR][COLOR=rgb(0, 0, 0)] protein kinase B/AKT; and [/COLOR][COLOR=rgb(44, 130, 201)]mTOR: [/COLOR][COLOR=rgb(0, 0, 0)]mammalian target of rapamycin. [/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Advantages of PDE5i in the Management of Glucose Metabolism Disorders
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top